SHELLY DAVIS: Open Payments
NPI 1386805885 · TIFTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,212 in 65 payments from 14 companies in 2025. Trend: 2023 $859 · 2024 $1,008 · 2025 $1,212
Food & beverage: $1,212
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $386 |
| AstraZeneca Pharmaceuticals LP | 7 | $174 |
| Novo Nordisk Inc | 10 | $167 |
| PFIZER INC. | 5 | $109 |
| Dexcom, Inc. | 5 | $86 |
| Lilly USA, LLC | 3 | $67 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 1 | $44 |
| IBSA Pharma Inc. | 2 | $31 |
| Medtronic, Inc. | 1 | $25 |
Products named: UBRELVY, VRAYLAR, Dexcom G6 Transmitter, QULIPTA, FARXIGA, Wegovy, LINZESS, Ozempic.
Industry payments across GA — which companies pay providers there.
